Open AccessQuetiapine: recent developments in preclinical research
Author(s) -
Marco Orsetti,
Fabio Di Brisco,
Massimo Mauro,
Dario Dallorto,
Piera Ghi
Publication year - 2010
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1.536
Subject(s) - medicine , quetiapine , mania , anxiety , schizophrenia (object oriented programming) , depression (economics) , antidepressant , bipolar disorder , psychiatry , neuroscience , bioinformatics , pharmacology , psychology , biology , cognition , economics , macroeconomics
Quetiapine (QTP) is an atypical antipsychotic labelled for the treatment of patients with schizophrenia, bipolar mania and bipolar depression. Nevertheless, QTP has been tried across multiple diagnosis categories and seems to be used, among other atypical antipsychotics, in clinical practice for an expanding range of disorders such as major depression, substance abuse disorders, anxiety disorders, and borderline personality disorders. The present review focuses on papers which investigated the molecular mechanism(s) of QTP antidepressant effect. In particular, preclinical studies performed by coupling the chronic mild stress, an animal model of human depression with Affymetrix microarray technology, revealed that chronic QTP administration prevented the stress-induced up- or down-regulation of 42 genes involved in the central nervous system development or having a crucial role for viability of neural cells, like regulation of signal transduction, inorganic ion transport, membrane organisation, and neurite morphogenesis. Among these, Ptgs2, Hes5, Plcb1, Senp2, Gad1, and Marcks are presumably the effectors of the QTP clinical efficacy